Title of the cohort
The Swedish National study on Aging and Care in Kungsholmen
Acronym for cohort
SNAC-K
Name of Principal Investigator
| Title | Professor |
| First name | Laura |
| Last name | Fratiglioni |
Address of institution where award is held
| Institution | Aging Reseach Center |
| Street Address | |
| City | Stockholm |
| Postcode | 113 30 |
Country
- Sweden
Website
www.ki-su-arc.se
Contact email
Funding source
1. The cohort includes, or expects to include, incidence of the following conditions
- Alzheimer’s disease and other dementias
- Parkinson’s disease
When studies on the above condition(s) are expected to become possible
- Already possible
2a. Stated aim of the cohort
To trace the changes in health status and detect factors leading to negative health and functional outcomes in the elderly
2b. Features distinguishing this cohort from other population cohorts
3a. i) Number of publications that involve use of cohort to date
4
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment
| Age in years from: | 60 + |
| To (‘until death’ if applicable): | until death |
4b. Study criteria: inclusion criteria
60 + living in Kungsholmen area at 2001
4c. Study criteria: exclusion criteria
No
5. Size of the cohort (i.e. number of participants enrolled)
- 1,000 – 5,000 participants
6a. Measures used to characterise participants
As well as biological and genetic date
6b. Additional measures for participants with a clinical disorder
Yes
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)
Dementia, Alzeimer, Parkinson and other cronical disorders
7. Study design
- Longitudinal
8. Cases matched by
- Other health assessment (specify) / N/A
- Not relevant
9a. Does the study include a specialised subset of control participants
- No
9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date
01-01-2001
10a. ii) Data collection end date
10a iii) Data collection for this study is
- Data collection ongoing
- Data analysis ongoing
10b. Plans to continue the cohort study beyond the current projected end date
- Yes – funding applied for
11. Data collected
- Only through the study
- Through links to medical records
12. System in place to enable re-contact with patients for future studies
- Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)
13a. Format and availability of data stored in a database
| Yes/No | % available | |
| Data summarised in database | yes | 100 |
| Database is web-based | ||
| Database on spreadsheet | yes | 100 |
| Database is on paper | yes | 100 |
| Other (specify) |
Language used:
Swedish
13b. Format and availability of data held as individual records
| Yes/No | % available | |
| Data held as individual records | ||
| Data is web-based | ||
| Data held on computer based records | yes | 100 |
| Data held on cards | ||
| Other (specify) |
Language used:
Swedish
14a. Are data available to other groups
Yes
14b. Access policy/mechanisms for access if data are available to other groups
- Resource has own ethics approval so usually no need for separate external ethics approval
15. Data sharing policy specified as a condition of use
- No policy exists
16a. Are tissues/samples/DNA available to other groups
Yes
16b. i) Description of available tissues/samples/DNA
- Living donors:blood
- Living donors: blood derivatives
- Living donors: DNA
16b. ii) Form available tissues/samples/DNA are supplied in
- Primary samples: Supplied fresh
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
17. Is information on biological characteristics available to other groups
- No
- Yes, for all the cohort